Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

In its upcoming report, Incyte (INCY) is predicted by Wall Street analysts to post quarterly earnings of $1.58 per share, reflecting an increase of 49.1% compared to the same period last year.

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares closed yesterday at $61.92. Easily identify stocks ...